Rubella Antibodies, IgG, Serum
Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test
Rubella (German or 3-day measles) is a member of the togavirus family and humans remain the only natural host for this virus. Transmission is typically through inhalation of infectious aerosolized respiratory droplets and the incubation period following exposure can range from 12 to 23 days.(1) Infection is generally mild and self-limited, and is characterized by a maculopapular rash beginning on the face and spreading to the trunk and extremities, fever, malaise, and lymphadenopathy.(2)
Primary, in utero rubella infections can lead to severe sequelae for the fetus, particularly if infection occurs within the first 4 months of gestation. Congenital rubella syndrome is often associated with hearing loss, cardiovascular and ocular defects.(3)
The United States 2-dose measles, mumps, rubella (MMR) vaccination program, which calls for vaccination of all children, leads to seroconversion in 95% of children following the first dose.(1) A total of 4 cases of rubella were reported to the CDC in 2011 without any cases of congenital rubella syndrome.(4) Due to the success of the national vaccination program, rubella is no longer considered endemic in the United States (cdc.gov/rubella). However, immunity may wane with age as approximately 80% to 90% of adults will show serologic evidence of immunity to rubella.
Determination of immune status to the rubella virus
Positive: Antibody index (AI) value > or =1.0
-The reported AI value is for reference only. This is a qualitative test and the numeric value of the AI is not indicative of the amount of antibody present. AI values above the manufacturer recommended cut-off for this assay indicate that specific antibodies were detected, suggesting prior exposure or vaccination.
-The presence of detectable IgG-class antibodies indicates immunity to the rubella virus through prior immunization or exposure. Individuals testing positive are considered immune to rubella infection.
Equivocal: AI value 0.8-0.9
Submit an additional sample for testing in 10 to 14 days to demonstrate IgG seroconversion if recently vaccinated or if otherwise clinically indicated.
Negative: AI value < or =0.7
The absence of detectable IgG-class antibodies suggests the lack of a specific immune response to immunization or no prior exposure to the rubella virus.
Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances
IgG-class antibodies to rubella virus may be present in serum specimens from individuals who have received blood products within the past several months, but who have not been immunized or experienced past infection with this virus.
Serum samples drawn early during acute phase of infection may be negative for IgG-class antibodies to this virus.
The presence of antirubella-IgG antibodies does not exclude the possibility of a recent or ongoing infection. Testing for IgM-class antibodies to rubella should be performed at a state health laboratory or at the CDC if the clinical presentation is suggestive of acute rubella infection.
Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.
Vaccinated: positive (> or =1.0 AI)
Unvaccinated: negative (< or =0.7 AI)
Clinical References Provides recommendations for further in-depth reading of a clinical nature
1. American Academy of Pediatrics. Rubella. In Red Book. 2012 Report of the Committee on Infectious Diseases. Edited by LK Pickering, Elk Grove Village, IL, 2012
2. Best JM: Rubella. Semin Fetal Neonatal Med 2007;12(3):182
3. Duszak RS: Congenital rubella syndrome-major review. Optometry 2009;80(1):36
4. Morbidity and Mortality Weekly Report: Notifiable Diseases and Mortality Tables 2012;61(34):466-479